Umicore acquires YPhos ligand technology from Ruhr-Bochum University

Precious Metals Chemistry

Umicore‘s business unit Precious Metals Chemistry is further expanding its cross-coupling catalyst portfolio by acquiring Ruhr-Bochum University’s YPhosTM ligands and catalysts technology.

Recognized as one of the most elegant and versatile synthetic methods to prepare high-value chemicals, cross-coupling reactions have become essential in the synthesis of agrochemicals, electronic chemicals, fine chemicals or pharmaceuticals. Invented by professor Viktoria Gessner’s research group, YPhosTM ligands are a novel class of phosphines bearing ylide substituents. They feature electronic and steric properties that show an excellent aptitude to support active transition metal catalysts, particularly in reactions where strong electron-donating ligands and steric protection of low coordinated species are required. 

Compared to the currently best known phosphine catalyst systems, YPhosTM ligands, combined with specific palladium-catalysts, showed a superior performance at room temperature Buchwald-Hartwig amination of aryl chlorides. They have additionally proven highly efficient in a wide range of challenging palladium-catalyzed α-arylation of alkyl ketones with aryl chlorides under mild conditions. Additionally, they feature outstanding performance in gold-catalyzed hydroamination and hydration reactions, using low catalyst loadings under mild reaction conditions.

Umicore now offers its customers worldwide a selection of YPhosTM ligand and catalyst systems on research and commercial scale. Research quantities are available from our distribution partner Merck/MilliporeSigma. This agreement with Ruhr-Bochum University enables Umicore to provide full access to an outstanding proprietary technology and to support its customers with an expanded portfolio of cutting-edge homogeneous catalysts and service offering, including Buchwald and Hazari precatalysts, Grubbs metathesis catalysts and many more. 

Depending on the region of publication, please note that:          

  • MilliporeSigma should be used in Canada and the USA
  • Merck should be used in the rest of the world.

For more information (in German), please find there PROvendis' publication for Ruhr University Bochum.

Please contact us for more information on YPhos technology.
Get in touch!